About

On the frontier of precision oncology

Tesselate Bio is a biotechnology company focusing on novel synthetic lethality approaches beyond Homologous Recombination Deficiency (HRD). We are discovering and developing new precision oncology medicines with the mission to turn cancer patients into cancer survivors.

Committed to Precision Medicine

We are leveraging a comprehensive development strategy early in our programs drive effective small molecule drug discovery towards novel, validated oncology targets and, critically, the parallel biomarker discovery and development of companion diagnostics.

Our Programs

ALT program

Targets cancers dependent on Alternative Lengthening of Telomeres (ALT).

Loss-of-Function (LoF) program

Targets cancers with tumor suppressor Retinoblastoma 1 (RB1) Loss-of-Function.

Tessellate Bio integrates best-in-class companion diagnostics.

I believe applying synthetic lethality beyond HRD has the potential to open a new frontier in precision oncology by addressing a wide range of cancer types with highly tumor-targeted treatments.

Andree Blaukat
CEO

Our Approach

Tessellate Bio brings together an international team with complementary skills and backgrounds to advance a pipeline of first-in-class tumor-targeting medicines.

Investors

Tesselate Bio is a private company supported by top-tier, global life science investors BioGeneration Ventures (BGV) and Forbion.

History

The company was initially founded and incubated by BioGeneration Ventures (BGV), with support from Daniela Couto, General Partner and the Leadership of Venture Partner, Andrew Lightfoot, a serial biotech entrepreneur and company builder.

Tessellate Bio’s initial programs are based on cutting-edge research from the international world-renowned researchers Hilda Pickett and Roger Reddell (Children’s Medical Research Institute, Australia), and Claus Azzalin (Instituto de Medicina Molecular (iMM), now the Gulbenkian Institute for Molecular Medicine (GIMM), Portugal).

Location

Tesselate Bio operates from its state-of-the art R&D facilities at the Stevenage Bioscience Catalyst, located at the heart of the UK’s golden triangle and also has offices in The Netherlands and Germany.